Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, said Thursday it has signed a production agreement with Tergus Pharma for both GLP and GMP materials associated with its novel cancer treatment drug, HT-001.
The production agreement comes as Hoth has requested a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration or FDA to discuss a proposed drug development program for the novel treatment.
HT-001 is a topical formulation designed for the treatment of patients with mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are used for treatment of cancers.
HT-001 is targeted to treat these EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy.
"Hoth management is pleased with the advancement of our HT-001 treatment throughout the developmental process. Patients struggling with dermatological ailments have been known to halt, and even discontinue potentially life-saving oncology treatments," said Robb Knie, CEO of Hoth Therapeutics.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.